Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 4/20 | 0.57 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | IDO1 | P14902 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 7/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL880421 | 0.92 | HSD17B10 (0.55) | HSD17B10LMNAMAPTSMN1; SMN2HTT | |
| SCHEMBL10280317 | 0.91 | HSD17B10 (0.54) | HSD17B10LMNAMAPTSMN1; SMN2HTT | |
| SCHEMBL10280620 | 0.86 | HSD17B10 (0.54) | HSD17B10LMNAMAPTSMN1; SMN2HTT | |
| SCHEMBL880307 | 0.85 | IDO1 (0.70) | HSD17B10LMNAMAPTSMN1; SMN2HTT | |
| SCHEMBL880232 | 0.83 | HSD17B10 (0.62) | HSD17B10LMNAMAPTSMN1; SMN2HTT | |
| SCHEMBL880290 | 0.83 | HSD17B10 (0.62) | HSD17B10LMNAMAPTSMN1; SMN2HTT | |
| SCHEMBL880249 | 0.82 | MAPT (0.58) | HSD17B10LMNAMAPTSMN1; SMN2HTT | |
| SCHEMBL880490 | 0.81 | LMNA (0.62) | HSD17B10LMNAMAPTSMN1; SMN2HTT | |
| SCHEMBL880355 | 0.81 | HSD17B10 (0.59) | HSD17B10LMNAMAPTSMN1; SMN2HTT | |
| SCHEMBL880420 | 0.81 | HSD17B10 (0.59) | HSD17B10LMNAMAPTSMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130289022-A1 | TETRAMERIC ALPHA-SYNUCLEIN AND USE THEREOF | BRANDEIS UNIVERSITY (US) | 2013-10-31 | — | — | US | disclosed |
| US-8440705-B2 | 2,3,4,7,8,9-hexahydro-1H-cyclopenta[h]quinolin-2-one or 2,3,4,6,7,8-hexahydro-1H-cyclopenta[g]quinolin-2-one; Alzheimer's disease | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2013-05-14 | — | — | US | disclosed |
| EP-2433634-A2 | Compounds, compositions and methods of inhibiting a-synuclein toxicity | The Whitehead Institute for Biomedical Research (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20100004277-A1 | COMPOUNDS AND METHODS FOR MODULATING PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| US-20100004277-A1 | COMPOUNDS AND METHODS FOR MODULATING PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| US-20080261953-A1 | Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261953-A1 | Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity | SNCA, PARK7, HTT | HSD17B10 1950/4885LMNA 525/4885MAPT 30/4885 |
| US-20100004277-A1 | COMPOUNDS AND METHODS FOR MODULATING PROTEIN TRAFFICKING | GOLT1B, NPC1L1, NPC1 | HSD17B10 3617/4885LMNA 3569/4885MAPT 640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.